Developing novel vaccines and therapeutic agents using dendritic cell receptor-targeted Chimigen® Platform Technology

Management Team

C. Satish Chandran Ph.D
Chief Executive Officer

Dr. Satish Chandran is the Chief Executive Officer of Akshaya Bio Inc. and also serves as Chief Executive Officer of Somahlution Inc.

Dr. Chandran is a distinguished biotech veteran with nearly 25 years of significant leadership experience in biotechnology. Previously, Dr. Chandran was Director of the Center for Excellence for Biopharmaceutical Research & Development and Professor of Pharmaceutics at North Dakota State University, the Chief Technology Officer of the Nucleic Acid-Based Therapeutics Unit in the BioTherapeutics Division at Pfizer, in Cambridge MA. While at Pfizer, he was also Professor at the Institute for Hepatitis and Virus Research in Doylestown, PA, USA. He was also Chief Operating Officer and Chief Scientific Officer at Nucleonics, in Horsham PA, the first RNAi based Biotechnology Company he co-founded while on the faculty at Thomas Jefferson University's Biochemistry Department.

Prior to founding Nucleonics, Dr. Chandran headed up the DNA Vaccine Division of Wyeth-Lederle Vaccines (following acquisition of Apollon, a biotech company in Malvern, PA), where his group advanced multiple DNA vaccine-based product candidates in infectious diseases and cancer into clinical studies.

Dr. Chandran received his Ph.D. from Memorial University in Newfoundland, Canada, and completed a post-doctoral fellowship at Fox Chase Cancer Center in Philadelphia. He is a strategic consultant and a member of the Board of Directors for several emerging and established biotechnology companies.

Rajan George, M.Sc, Ph.D
Founder, President & Chief Scientific Officer

Dr. Rajan George is the Founder, President and Chief Scientific Officer of Akshaya Bio Inc., a biotechnology company developing vaccines as well as other biotherapeutic agents.

Previously, Dr. George was Executive Vice President and Chief Technology Officer of Paladin Biosciences, a division of Paladin Labs Inc. (TSX:PLB), Edmonton, Alberta, Canada. He holds Adjunct Faculty appointment in the Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. The focus is on the development of therapeutic vaccines for chronic viral infections such as Hepatitis B and Hepatitis C.

Dr. George is the co-inventor of ChimigenĀ® Vaccine Platform technology which received the Alberta Science and Technology award for innovation in 2004. He was the recipient of a Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation in 2009. Dr. George was Senior Vice President of Research and Development and a founding member of ViRexx Medical Corp., (TSX:VIR, AMEX:REX), Edmonton, Alberta, Canada, before Paladin acquisition.

Previously, a Research Scientist at the Glaxo Heritage Research Institute, University of Alberta, Edmonton, Canada, where the field of research was Hepatitis B virology and antiviral therapy. Dr. George received a Ph.D in Biochemistry from the Indian Institute of Sciences (Bangalore, India). He also had postdoctoral training at the University of Wisconsin in Madison, WI, USA and the University of Alberta (Edmonton, Alberta, Canada).